Sheppard Mullin Advises Underwriters in connection with HCW Biologics' Initial Public Offering
Sheppard Mullin advised the underwriters in connection with a $56 million initial public offering of Common Stock of HCW Biologics, Inc. HCW Biologics’ shares began trading on the Nasdaq Capital Market on July 20, 2021 under the ticker symbol “HCWB.” HCW Biologics is an innovative preclinical stage biopharmaceutical company focused on discovering and developing novel immunotherapies to lengthen health span by disrupting the link between chronic, low-grade inflammation and age-related diseases.
The Sheppard Mullin corporate team included partners Richard Friedman and Stephen Cohen, associate Taylor Ashton and law clerk Brett Uslaner. Partner Jing Liu provided advice on Intellectual Property matters, and Partner Allison Fulton provided advice on FDA Regulatory matters. Members of the Sheppard Mullin team are based in the New York, Del Mar, Los Angeles and Washington, D.C. offices.
Click here to read the press release.